# DeLLphi-309: HCP commentary report

> 206 verified statements (59 from speakers with a confirmed clinical role) from 39 commentary sources · 8 findings · updated Oct 27, 2026

## Report

- Trial: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
- NCT ID: NCT06745323
- Registry: https://clinicaltrials.gov/study/NCT06745323
- Sponsor: Amgen
- Phase: Phase 2
- Status: Active, not recruiting
- Indications: Small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-27
- Last checked: 2026-10-27
- Release hash: 3f6f4cc2230a271908f1790dec95f67e258fa3a8876848c96ffa362c856b2bf9

## Counts

- HCP commentary sources screened: 58
- Sources cited by verified statements: 39
- Verified statements: 206
- From speakers with a confirmed clinical role: 59
- Findings: 8
- People found in screened sources: 31
- People identity-verified: 25
- Voices cited: 31
- Organisational or shared accounts (not counted as people): 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

DeLLphi-309 asks whether less-frequent tarlatamab can maintain treatment benefit in small-cell lung cancer that has progressed after initial chemotherapy. Clinicians in the sources reviewed for this edition express interest in longer intervals without agreement on interchangeable schedules. Dosing flexibility draws enthusiasm, while survival interpretation and treatment burden draw scrutiny. Long-term outcomes and the separate implications of visit frequency and initial observation remain open.

## Open Medical Affairs question

What evidence and patient-service safeguards would make Q3W or Q4W an acceptable trade-off without sacrificing clinically important activity?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Interest in longer intervals does not amount to agreement on interchangeable schedules
- F2. Broad safety reassurance is repeatedly qualified by CRS, ICANS and serious-event observations
- F3. Non-estimable survival prompts a question about maturity, not a conclusion of treatment success
- F4. Visit frequency and initial observation are separate burdens, with different safeguards
- F5. In resource-limited settings, preferred treatment depends on whether the criterion is experience or deliverability
- F6. Enthusiasm for later-line tarlatamab is qualified by who can reach and tolerate treatment
- F7. CNS confidence differs, and local-treatment decisions remain conditional rather than automatic
- F8. Safe delivery is described as a whole-workforce capability, especially outside major centers

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 19 | 16 | 13 | 8 | recorded | 2 |
| F2 | 10 | 8 | 6 | 5 | recorded | 3 |
| F3 | 6 | 7 | 4 | 3 | recorded | 2 |
| F4 | 19 | 9 | 6 | 7 | recorded | 3 |
| F5 | 17 | 8 | 1 | 3 | recorded | 3 |
| F6 | 17 | 14 | 4 | 8 | recorded | 5 |
| F7 | 13 | 6 | 2 | 2 | recorded | 3 |
| F8 | 15 | 9 | 2 | 4 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 0 | 0 | 5 | 7 | 20 | 3 | 12 posts and articles, 1 podcast or video | yes |
| F2 | 3 | 0 | 0 | 7 | 0 | 10 | 5 | 5 posts and articles, 1 podcast or video | yes |
| F3 | 3 | 1 | 0 | 2 | 0 | 6 | 5 | 3 posts and articles, 1 podcast or video | yes |
| F4 | 14 | 1 | 1 | 1 | 2 | 20 | 0 | 4 posts and articles, 2 podcasts and video | yes |
| F5 | 8 | 2 | 1 | 4 | 2 | 18 | 2 | 1 podcast or video | yes |
| F6 | 10 | 2 | 1 | 0 | 4 | 17 | 1 | 2 posts and articles, 2 podcasts and video | yes |
| F7 | 9 | 2 | 1 | 1 | 0 | 13 | 2 | 2 podcasts and video | yes |
| F8 | 8 | 1 | 2 | 1 | 3 | 17 | 1 | 1 post or article, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab: F1 (6 shared claims), F2 (1 shared claims), F3 (1 shared claims)
- Primary endpoint: Proportion of participants with complete response to Tarlatamab: no finding draws on it directly
- Primary endpoint: Proportion of participants with partial response to Tarlatamab: no finding draws on it directly
- Secondary endpoints: F1 (8 shared claims), F2 (3 shared claims), F3 (5 shared claims)
- Population and setting: F6 (14 shared claims), F7 (3 shared claims)
- The comparison: F1 (11 shared claims), F2 (3 shared claims), F3 (2 shared claims), F4 (5 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (9 shared claims), F6 (1 shared claims), F8 (8 shared claims)
- Design and conduct: F1 (6 shared claims), F2 (1 shared claims), F3 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F3. Non-estimable survival prompts a question about maturity, not a conclusion of treatment success

A participant in a YouTube discussion asks how to interpret non-estimable overall survival in the longer-interval groups.

The questioner's identity and clinical role are not stated in the source.

Source: YouTube video, 2026-09-13.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 206 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 39 | Counts free |
| Speaker attribution for cited voices | 31 | Paid |

## Trial aspects

13 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab | discussed | 8 | 8 |
| Primary endpoint: Proportion of participants with complete response to Tarlatamab | no commentary found | 0 | 0 |
| Primary endpoint: Proportion of participants with partial response to Tarlatamab | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 16 | 10 |
| Population and setting | discussed | 20 | 3 |
| The comparison | discussed | 24 | 18 |
| Safety and tolerability | discussed | 19 | 8 |
| Design and conduct | discussed | 8 | 7 |
| Time toxicity, travel and care-provider burden | discussed | 13 | 5 |
| Observation requirements and patient-support conditions | discussed | 10 | 7 |
| Relapsed-treatment alternatives, affordability and geographic access | discussed | 30 | 3 |
| CNS confidence and selective local-versus-systemic treatment | discussed | 23 | 2 |
| Workforce preparation and equitable treatment reach | discussed | 15 | 1 |
| Attention to the study and the strength of endorsement | discussed | 9 | 13 |
| Clinical-value interpretation beyond a single radiographic endpoint | discussed | 11 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 49 | 33 |
| YouTube | 5 | 3 |
| Podcasts | 3 | 3 |
| Bluesky threads | 1 | 0 |

- Screened window: 2024-01-08 to 2026-10-14
- Cited window: 2025-04-23 to 2026-10-14
- Retrieved: 2026-10-27

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
- Registry: NCT06745323 (https://clinicaltrials.gov/study/NCT06745323)
- Study IDs: 20240092
- Sponsor: Amgen
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 252 (actual)
- Start: 2025-02-26 (actual)
- Primary completion: 2029-08-10 (estimated)
- Primary endpoint: Proportion of participants with confirmed objective response to Tarlatamab (Approximately 52 Months)
- Primary endpoint: Proportion of participants with complete response to Tarlatamab (Approximately 52 Months)
- Primary endpoint: Proportion of participants with partial response to Tarlatamab (Approximately 52 Months)
- Intervention: Tarlatamab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on biomarker-guided patient selection and subtype-specific treatment in small cell lung cancer.
- Not yet captured in this edition: a question about financial toxicity in maintenance and subsequent treatment decisions for small cell lung cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed are not a representative sample of all HCP opinion. Reposts, organizational accounts, repeated summaries and versions of the same discussion must not be counted as independent clinicians or consensus.
- Some potentially relevant passages were not fully assessed, and discussion using unnamed or differently transcribed study references may be absent. Missing commentary cannot establish lack of interest or concern.
- No full publication for NCT06745323, protocol or exact tarlatamab regulatory label was available for independent reconciliation. Results, regulatory updates and management practices remain attributed accounts where stated.
- DeLLphi-309's presented analysis was descriptive, with no hypotheses formally tested. Similarity language does not establish equivalence, and numerical differences do not establish inferiority.
- Survival follow-up was approximately nine months in the accounts discussed. Unreached or non-estimable medians do not establish schedule-specific treatment success.
- Delivery and hospitalization statements come from different dates, settings and purposes. They should not be combined into a single current administration standard or interpreted as evidence of a change of mind.
- Clinical roles are not independently confirmed for several named contributors. A confirmed name or account identity is not confirmation of clinical credentials; the advocate perspective is distinguished from HCP commentary.
- Some source passages do not establish who spoke. Their views remain anonymous, and named passages elsewhere do not resolve that uncertainty.
- Earlier Phase 3, single-arm or alternative-treatment observations are not DeLLphi-309 results. No schedule-specific CNS conclusion or direct tarlatamab-versus-ADC comparison can be drawn from these discussions.
- One duration-of-response value in the press-briefing transcript is unclear. The report does not infer a corrected value from that transcript.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-27: current edition

Last checked for new commentary 2026-10-27. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (206 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (25 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/dellphi-309-nct06745323
- Agents: POST https://www.erudio.com/api/orders with {"report": "dellphi-309-nct06745323", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=dellphi-309-06745323

## Cite

Erudio Health. DeLLphi-309 (NCT06745323): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 27, 2026. https://www.erudio.com/reports/dellphi-309-nct06745323

## Machine access

- JSON: https://www.erudio.com/reports/dellphi-309-nct06745323.json
- Markdown: https://www.erudio.com/reports/dellphi-309-nct06745323.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "dellphi-309-06745323"}`